Astrogliosis in aging and Parkinson’s disease dementia: a new clinical study with $^{11}$C-BU99008 PET

Mohamed A. Mohamed,1,* Zhou Zeng,1,2,* Marta Gennaro,1 Nicholas P. Lao-Kaim,1 Jim F. M. Myers,1 Valeria Calsolaro,1 Grazia Daniela Femminella,1,3 Robin J. Tyacke,1 Antonio Martin-Bastida,1,4 Roger N. Gunn,1 David J. Nutt,1 Paul Edison,1 Paola Piccini1,* and Andreas-Antonios Roussakis1,*

* These authors contributed equally to this work.

The role of astrogliosis in the pathology of brain aging and neurodegenerative diseases has recently drawn great attention. Imidazoline-2 binding sites represent a possible target to map the distribution of reactive astrocytes. In this study, we use $^{11}$C-BU99008, an imidazoline-2 binding sites-specific PET radioligand, to image reactive astrocytes in vivo in healthy controls and patients with established Parkinson’s disease dementia. Eighteen healthy controls (age: 45–78 years) and six patients with Parkinson’s disease dementia (age: 64–77 years) had one $^{11}$C-BU99008 PET-CT scan with arterial input function. All subjects underwent one 3 T MRI brain scan to facilitate the analysis of the PET data and to capture individual cerebral atrophy. Regional $^{11}$C-BU99008 volumes of distribution were calculated for each subject by the two-tissue compartmental modelling. Positive correlations between $^{11}$C-BU99008 volumes of distribution and age were found for all tested regions across the brain within healthy controls ($P < 0.05$); furthermore, multiple regression indicated that aging affects $^{11}$C-BU99008 volumes of distribution values in a region-specific manner. Independent samples $t$-test indicated that there was no significant group difference in $^{11}$C-BU99008 volumes of distribution values between Parkinson’s disease dementia ($n = 6$; mean age = 71.97 ± 4.66 years) and older healthy controls ($n = 9$; mean age = 71.90 ± 5.51 years). Our data set shows that astrogliosis is common with aging in a region-specific manner. However, in this set-up, $^{11}$C-BU99008 PET cannot differentiate patients with Parkinson’s disease dementia from healthy controls of similar age.
**Introduction**

Astrocytes change morphology and functions in response to physiological aging, as well as to pathological stimuli, such as neurodegenerative diseases, infection, trauma, tumours, and ischaemia, through a process known as reactive astrogliosis (also termed as astrogliosis).\(^1,2\)

Data from preclinical assays suggest that reactive astrocytes are involved in the progression of Parkinson’s disease,\(^3\) and Alzheimer’s\(^4\) diseases. Many experts in the field consider dementia in Parkinson’s disease (PDD) a sign of advanced Parkinson’s disease. However, the literature is inconclusive on the role of astrocytes in it. To our knowledge, no imaging study has yet examined the pattern of regional astrogliosis in PDD and its relation to brain aging. To date, only two PET radiotracers are available to image astrogliosis.\(^5\) Of these, the most well-known is \(^{11}\)C-deuterium-L-deprenyl (\(^{11}\)C-DED), which binds irreversibly to the monoamine oxidase-B (MAO-B) and has been used to study Alzheimer’s disease, Creutzfeldt-Jakob disease, amyotrophic lateral sclerosis, and focal epilepsy.\(^6–9\)

MAO-B is expressed on the outer mitochondrial membrane and is highly related with astrocytes. See relation with dopamine breakdown and the rationale of treating Parkinson’s disease with monoamine oxidase inhibitors (MAO-Is).

More recent work, using the relatively novel ligand, \(^{11}\)C-BU99008, which targets the imidazoline type-2 binding sites (I\(_2\)BS) of the astrocyte mitochondrial membranes, enable the latter radiotracer as a promising biomarker of studying astrogliosis in vivo.\(^3,10,11\) The first publication with \(^{11}\)C-BU99008 PET in healthy controls (HCs), presents \(^{11}\)C-BU99008 as a tracer with a good global brain uptake and specific binding signal that is consistent with I\(_2\)BS distribution known from pathology studies.\(^12\) More recently, \(^{11}\)C-BU99008 PET showed high levels of regional I\(_2\)BS...
density in people with early Parkinson’s disease\textsuperscript{13} as well as in patients with established Alzheimer’s disease.\textsuperscript{14,15}

The current study aims to investigate regional astrogliosis \textit{in vivo} (with $^{11}$C-BU99008 PET) in patients with PDD and HCs. Secondarily, the study explores the role of aging on regional L\textsubscript{i}BS distribution.

**Materials and methods**

**Participants**

We included six patients with PDD between 64 and 77 years of age (mean age: 71.97 ± 4.66) and eighteen HCs, between 45–78 years of age (mean age: 61.94 ± 11.79), who did not have a family history of Parkinson’s disease. Patients were recruited from the Specialist Movement Disorders NHS Clinics, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK. All patients had established idiopathic Parkinson’s disease according to the UK Parkinson’s Disease Queen Square diagnostic criteria.\textsuperscript{16} The diagnosis of PDD was made using the clinical criteria of the Movement Disorders Society for probable PDD.\textsuperscript{17}

HCs were recruited as discussed elsewhere.\textsuperscript{13} None of the HCs was taking medication with direct action on the CNS. All subjects (HCs and patients with PDD) were able to undergo MRI scanning. None of the patients was ever treated with MAO-I s. Severity of Parkinson’s disease symptoms was assessed using the modified Hoehn and Yahr staging scale\textsuperscript{18} and the Movement Disorders Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS).\textsuperscript{19} Global cognitive function was evaluated using the mini-mental state examination (MMSE),\textsuperscript{20} the Montreal cognitive assessment (MoCA)\textsuperscript{21} and the Parkinson’s disease Clinical Rating Scale (Parkinson’s disease-CRS).\textsuperscript{22} In this protocol, the following scores were deemed indicative for PDD: MMSE scores below 26, MoCA scores below 25, and Parkinson’s disease-CRS total scores ≤81. Read more about this approach elsewhere.\textsuperscript{23} Neuropsychiatric symptoms were assessed using the Neuropsychiatric Inventory (NPI).\textsuperscript{24} All patients were assessed clinically in the ‘off’ medication state. Clinical assessments took place at the NIHR Imperial Clinical Research Facility (London, UK) within a month prior to the imaging procedures.

Local Research Ethics Committee approvals were obtained before recruitment took place [National Research Ethics Services References: 17/NW/0009 (PDD subjects), 14/LO/1741 and 15/LO/1609 (HCs)]. All participants provided their written consent in accordance with the Declaration of Helsinki. Each sub-project was approved by the Health Research Authority, the Imperial Joint Research Office, and the UK Administration of Radioactive Substances Advisory Committee.

**Scanning procedures**

All imaging was performed at Invicro LLC imaging facility (London, UK). $^{11}$C-BU99008 PET scans were acquired on a Siemens Biograph TruePoint HI-REZ 6 PET/CT system (Siemens Healthcare). In brief, a low-dose CT transmission scan (0.36 mSv) was performed prior to radioligand injection for attenuation-correction and anatomical localisation purposes.

$^{11}$C-BU99008 was intravenously administered as a bolus injection (mean injected dose of 286.46 ± 28.56 MBq); dynamic emission data were acquired for 120 minutes after injection. The imaging data were reconstructed using a filtered back-projection algorithm (direct inversion Fourier transform; matrix size: $128 \times 128$, zoom: 2.6, 5 mm transaxial Gaussian filter, pixel size: 2 mm isotropic) and then binned into 29 frames. Before the administration of the radioligand, an arterial line was placed in the radial artery by experienced PET imaging physicians, following local anaesthesia and safety measures including Allen testing. Through this line, arterial blood was sampled continuously for the first 15 min of the scan. In addition, discrete blood samples were manually withdrawn at 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 110, and 120 min after $^{11}$C-BU99008 venous injection.

$T_1$-weighted structural MR brain images were acquired on a 3T Siemens Magnetom Trio system with a 32-channel head coil (MPRAGE; repetition time = 2300 ms, echo time = 2.98 ms, flip angle 9°, time to inversion = 900 ms, slice thickness 1 mm, matrix size $240 \times 256$ mm) to facilitate PET anatomical identification, and to assess the extent of regional volume loss (patients with PDD only).

**MRI data analysis**

Subcortical nuclei volumes and cortical thickness were assessed from MRI data using FreeSurfer image analysis suite (version 6.0.0; \texttt{http://surfer.nmr.mgh.harvard.edu}) with a surface-based (cortical) and volume-based (subcortical) approach, as previously described.\textsuperscript{25} Briefly, the software executed skull-stripping, automated Talairach transformation, segmentation of the subcortical white matter and the deep grey matter volumetric structures, intensity normalisation, tessellation of the grey matter/white matter boundary, automated topology correction, intensity gradients based surface deformation to product grey/white matter and grey/cerebrospinal fluid surface model, and brain inflation. The volumes of subcortical nuclei were measured automatically from FreeSurfer’s output and normalized using total intracranial volume, also provided by FreeSurfer, to account for between-person variations in head size.

**PET image processing**

PET and MR (MPRAGE) images and blood sample data were analysed using MIKAT\textsuperscript{TM} software version 4.2.6 for academic purposes (Molecular Imaging and Kinetic Analysis Toolbox, Imanova Ltd),\textsuperscript{26} which was implemented on MATLAB (MathWorks Inc.), utilizing FSL 6.0 (FMRIB Image Analysis Group) and SPM 12 (Statistical Parametric
Mapping, Wellcome Trust Centre for Neuroimaging) functions.

Structural MPRAGE images were segmented and rigid registered to the standard Montreal Neurological Institute (MNI) template. An MNI-based regional atlas (CIC Atlas v1.2; GlaxoSmithKline Clinical Imaging Centre) was non-linearly warped to the registered MPRAGE images to define regions of interest (ROI: whole brain, cortical regions, sub-cortical regions, cerebellum, brainstem, frontal cortex, occipital cortex, temporal cortex, parietal cortex, cingulate cortex, insula, hippocampus, striatum and thalamus).

Dynamic PET images were motion-corrected using rigid registration to reference frame 16. Signal-averaged (summed) images were created to define the co-registration parameters to corresponding MPRAGE images. ROI maps from the registered atlases were overlaid on the dynamic PET images to enable modelling of regional time-activity curves. Parent plasma input functions were calculated from the arterial blood samples. The whole-blood data were corrected for plasma and metabolite fractions and were interpolated with a triexponential function. These data were used as input function in a two-tissue compartment model with 5% fixed blood volume, which has been shown as the most suitable model to calculate \(^{11}\text{C-BU99008 VT}\) values.

To address potential bias from partial volume effects due to brain atrophy, we applied partial volume correction (PVC) on \(^{11}\text{C-BU99008 PET Images}\) for patients with PDD and a subgroup within HCs (see definition of subgroups below) using the PETPVE12 toolbox. PVC was performed with the voxel-based Müller-Gartner compartmental model using the MRI-registered tissue segments derived as part of the main analysis pipeline. Corrected PET images were then generated from the co-registered dynamic series through an automated process, with a frame-by-frame approach. After that stage, corrected images were re-introduced on MIAKAT software. Respective \(^{11}\text{C-BU99008 VT}\) values were calculated with and without PVC.

**Statistical analyses**

All statistical analyses were performed with SPSS statistics (version 20); graphs were created using GraphPad Prism (version 6.0) for MAC OS X. Imaging and clinical numerical variables were tested for normality and equality of variances using Shapiro–Wilk and Levene’s tests, respectively. The level of significance was set at \(a = 0.05\). Comparisons of means was made with independent samples \(t\)-test and Mann–Whitney \(U\) test, as appropriate. Within HCs, the association between age and regional \(^{11}\text{C-BU99008 VT}\) values was sought by non-parametric Spearman’s rho. Benjamini-Hochberg correction procedure was applied.

To understand the effect of aging on astroglialosis, HCs were divided according to quartiles to: older healthy controls (OHCs) and younger healthy controls (YHCs). The differential effects of age on \(^{11}\text{C-BU99008 VT}\) values across brain regions (cortical, subcortical areas and cerebellum) were compared via multiple linear regression (dependent variable: \(^{11}\text{C-BU99008 VT}\), independent variables: region, age and age-by-region interaction; with cerebellum as a reference region). All assumptions for multiple regression were met. To assess differences of regional \(^{11}\text{C-BU99008 VT}\) values, with or without PVC, between patients with PDD and OHC, independent samples \(t\)-tests were conducted separately for each ROI. Comparisons between groups on FreeSurfer

---

**Table 1** Characteristics of healthy controls and patients with PDD

|          | PDD            | OHC (n = 9) | YHC (n = 9) |
|----------|----------------|-------------|-------------|
| Age (years) | 71.97 ± 4.66   | 71.90 ± 5.51*** | 51.97 ± 6.47*** |
| Gender    | 3F:3M          | 2F:7M       | 1F:8M       |
| PD duration (years) | 7.37 ± 3.21    | —           | —           |
| PDD duration (years) | 1.05 ± 0.57    | —           | —           |
| Hoehn and Yahr | 3.33 ± 0.52    | —           | —           |
| MDS-UPDRS Total | 88.83 ± 26.78  | —           | —           |
| MDS-UPDRS-Part I | 10.83 ± 1.83   | —           | —           |
| MDS-UPDRS-Part II | 19.83 ± 10.85  | —           | —           |
| MDS-UPDRS-Part III | 51.00 ± 15.35  | —           | —           |
| NPI total | 2.83 ± 1.46    | —           | —           |
| NPI-Hallucinations | 0.50 ± 0.50    | —           | —           |
| NPI-Depression | 1.00 ± 1.00    | —           | —           |
| NPI-Anxiety | 0.67 ± 0.47    | —           | —           |
| Daily LED\(_{total}\) (mg) | 387.17 ± 310.56 | —           | —           |
| MMSE     | 21.17 ± 5.42   | —           | —           |
| MoCA     | 15.33 ± 6.19   | —           | —           |
| PD-CRS   | 52.83 ± 17.23  | —           | —           |

Values are shown as means ± SD. PDD scores calculated in ‘off’ medication state.

***denotes significant at \(P < 0.001\); ns, not statistically significant. Comparisons were made between PDD (\(n = 6\)) and OHC (\(n = 9\)) and between PDD and YHC (\(n = 9\)); independent samples \(t\)-test (one-tailed).

PDD, Parkinson’s disease dementia; OHC, older healthy controls; YHC, younger healthy controls; ns, not significant; F, female; M, male; MDS-UPDRS, Movement Disorders Society Unified Parkinson’s disease rating scale; daily LED\(_{total}\), daily total levodopa equivalent dose; MMSE, mini-mental state examination; MoCA, Montreal cognitive assessment; Parkinson’s disease-CRS, Parkinson’s disease Clinical Rating Scale.
MRI data were performed with Mann–Whitney U tests (two-tailed).

**Data availability**
The authors confirm that the data supporting the findings of this study are available within the article and its supplementary material.

**Results**

**Demographics and clinical characteristics**

Table 1 summarizes the demographics and clinical characteristics of all participants. There was no significant difference in age between patients with PDD and OHC ($P > 0.05$). PDD patients were significantly older than the YHC ($P < 0.001$). Comparisons between PDD and HC groups refer to independent samples $t$-test (one-tailed).

**PET data analysis**
The distribution of regional $^{11}$C-BU99008 binding for patients with PDD, OHC and YHC are presented in Table 2 and Figs. 1 and 2.

**Between-group comparisons**

Independent samples $t$-test indicated no significant difference in regional $^{11}$C-BU99008 $V_T$ values, between PDD and OHC, or between PDD and the entire HC group. Differences in regional $^{11}$C-BU99008 $V_T$ were sought post-PVC (corrected); these results were consistent with those derived without PVC—see supplementary Table 1.

Both PDD and OHC groups had higher $^{11}$C-BU99008 $V_T$ values in subcortical areas as compared with the cerebellum ($P < 0.05$). No significant difference was found between these groups in $^{11}$C-BU99008 $V_T$ for either cortical or cerebellar values. Similarly, no regional difference was identified between PDD and OHC or between PDD and the entire HC group.

**Correlations**

There was no statistically significant correlation between regional $^{11}$C-BU99008 $V_T$ values and clinical scores including motor (MDS-UPDRS) and cognitive (MMSE, MoCA, Parkinson’s disease-CRS) scores. Within all 18 HCs, Spearman’s rho testing revealed moderate-strong correlations between age and $^{11}$C-BU99008 $V_T$ values in the frontal ($r = +0.51$, $P < 0.05$), occipital ($r = +0.66$, $P < 0.01$), temporal ($r = +0.55$, $P < 0.01$), parietal ($r = +0.64$, $P < 0.01$), insular ($r = +0.49$, $P < 0.05$), and cingulate cortices ($r = +0.51$, $P < 0.05$), hippocampus ($r = +0.44$, $P < 0.05$), striatum ($r = +0.47$, $P < 0.05$), thalamus ($r = +0.57$, $P < 0.01$), cerebellum ($r = +0.54$, $P < 0.01$) and brainstem ($r = +0.58$, $P < 0.01$).

**Age effects**

A significant age-by-region interaction was observed in HCs, revealing differential age effects on $^{11}$C-BU99008 $V_T$ values for each region. As shown in Fig. 3, the effect of aging on $^{11}$C-BU99008 $V_T$ was more prominent in subcortical regions, compared to the cerebellum ($P < 0.05$). $^{11}$C-BU99008 $V_T$ values were significantly higher in subcortical and cortical regions than in the cerebellum ($P < 0.001$), irrespective of age. We found no significant effect of age on $^{11}$C-BU99008 $V_T$ when values were collapsed across regions. The results of multiple linear regression are presented in Table 3.

**MRI data analysis**

Patients with PDD had significant volume losses as compared with OHC in several brain regions. Comparisons refer to Mann–Whitney U test (two-tailed) between PDD and OHC or between OCH and YHC. Volumetric analyses showed a significant reduction in the left hippocampus (PDD: $3.24 \pm 0.29$ cm$^3$, OHC: $3.91 \pm 0.17$ cm$^3$, two-tailed Mann–Whitney U test, $U = 0$, $P < 0.05$) and right hippocampus (PDD: $3.47 \pm 0.33$ cm$^3$, OHC: $4.13 \pm 0.32$ cm$^3$, two-tailed Mann–Whitney U test, $U = 1$, $P < 0.05$), right putamen (PDD: $3.63 \pm 0.63$ cm$^3$, OHC: $4.47 \pm 0.34$ cm$^3$, two-tailed Mann–Whitney U test, $U = 2$, $P < 0.05$), left amygdala (PDD: $1.49 \pm 0.23$ cm$^3$, OHC: $1.80 \pm 0.30$ cm$^3$, two-tailed Mann–Whitney U test, $U = 5$, $P < 0.05$), and right nucleus

| Region            | PDD ($n = 6$) | HCs ($n = 18$) | OHC ($n = 9$) | YHC ($n = 9$) |
|-------------------|--------------|---------------|--------------|---------------|
| Frontal cortex    | $59.09 \pm 9.81$ | $56.19 \pm 6.85$ | $57.97 \pm 6.93$ | $54.41 \pm 6.67$ |
| Occipital cortex  | $50.29 \pm 11.17$ | $52.22 \pm 7.86$ | $54.95 \pm 8.65$ | $49.49 \pm 6.31$ |
| Temporal cortex   | $64.64 \pm 12.32$ | $63.40 \pm 8.58$ | $66.16 \pm 8.47$ | $60.65 \pm 8.23$ |
| Parietal cortex   | $53.68 \pm 8.07$ | $53.38 \pm 7.12$ | $55.71 \pm 7.57$ | $51.04 \pm 6.18$ |
| Insular cortex    | $75.26 \pm 14.37$ | $73.33 \pm 9.22$ | $75.84 \pm 9.73$ | $70.81 \pm 8.48$ |
| Hippocampus       | $84.85 \pm 20.03$ | $80.81 \pm 13.13$ | $84.62 \pm 11.69$ | $76.99 \pm 14.04$ |
| Cingulate         | $68.64 \pm 12.05$ | $69.37 \pm 8.91$ | $71.74 \pm 8.61$ | $66.10 \pm 9.06$ |
| Thalamus          | $92.71 \pm 21.56$ | $90.22 \pm 12.23$ | $94.19 \pm 10.49$ | $86.25 \pm 13.13$ |
| Striatum          | $126.59 \pm 35.55$ | $119.72 \pm 19.39$ | $125.75 \pm 15.95$ | $113.69 \pm 21.52$ |
| Cerebellum        | $48.52 \pm 11.57$ | $46.83 \pm 7.26$ | $48.76 \pm 5.86$ | $44.89 \pm 4.85$ |
| Brainstem         | $71.26 \pm 16.13$ | $71.43 \pm 9.87$ | $75.46 \pm 8.86$ | $67.41 \pm 9.59$ |

Values are shown as means ± SD.
PDD, Parkinson’s disease dementia; HCs, healthy controls; OHC, older healthy controls; YHC, younger healthy controls.
accumbens (PDD: 0.38 ± 0.04 cm³, OHC: 0.47 ± 0.06 cm³, two-tailed Mann–Whitney U test, U = 3, P < 0.05). PDD data refer to direct comparison with data from the OHC group (P < 0.05). Significant volume losses were also observed in the brainstem of the OHC group as compared with YHC (OHC: 20.37 ± 1.67 cm³, YHC: 23.10 ± 2.96 cm³, two-tailed Mann–Whitney U test, U = 15, P < 0.05). See more in supplementary Table 2.

**Discussion**

This is the first PET imaging study with ¹¹C-BU99008 to explore the extent of astrogliosis in PDD. We found that I₂BS density relates to old age in a region-dependent manner as reflected by data from HCs. However, I₂BS density values did not differentiate patients with PDD from healthy subjects of similar age.

In HC groups, I₂BS density values, across the brain, correlated positively with age, suggesting that astrogliosis is more common as individuals get older. This finding is in line with ¹¹C-DED PET human studies in HCs—reference to MAO-B density increases.²⁹,³⁰ This point is supported by evidence stemming from post-mortem and animal studies on the astrocytic glial fibrillary acidic protein (GFAP).³⁰–³² The GFAP helps astrocytes maintain their structural integrity and to achieve (in the reactive state) cell movement. The GFAP is believed to increase in the cytoplasm of astrocytes, when dramatic changes in their shape are required. Alterations in reactive astrocytes of humans, non-human primates and rats, implicate GFAP as a significant site for research.³¹–³³ Although, to our knowledge, there is no GFAP-specific PET radioligand for human use. As astrocytic I₂BS density relates to high GFAP expression,³⁴,³⁵ we suggest that brain imaging with ¹¹C-BU99008 PET represents a valuable marker of reactive astrocytosis in vivo.³,¹²,¹³

Our HC group data demonstrate that aging affects global I₂BS density albeit with some preference to the brain regions known from preclinical and pathology studies³²,³⁶,³⁷ to be most vulnerable to degeneration. Our PDD data support this view suggesting that astroglisis in a region-specific manner reflects selective vulnerability to progressive neuronal loss. Future work will be required to explore the impact of aging-related astroglisis on neuronal networks, and the chronology of cognitive impairment and motor dysfunction in Parkinson’s disease.

**Figure 1 Regional distribution volumes.** Graph shows regional ¹¹C-BU99008 distribution volumes (Vₚ) in PDD patients (n = 6) and healthy controls (OHC, n = 9; YHC, n = 9). Vₚ, volume of distribution; PDD, Parkinson’s disease patients with dementia; OHC, older healthy controls; YHC, younger healthy controls.
Our findings describe similar levels of cerebral I$_2$BS binding between the PDD and OHC groups. Unfortunately, external evidence from studies on astrogliosis within PDD is limited to further support this finding. Two post-mortem studies have shown the presence of reactive astrocytes in the substantia nigra of Parkinson’s disease patients, some of whom were demented, whereas others could not demonstrate a robust difference in astrogliosis patterns between demented/non-demented Parkinson’s disease patients and HCs. In a recent study, $^{11}$C-BU99008 PET data from patients with early Parkinson’s disease showed high global I$_2$BS binding as compared with HCs. Under the same imaging protocol, global I$_2$BS binding was relatively low in patients with moderate/advanced Parkinson’s disease, as compared with data from both early stage Parkinson’s disease and HCs. In this PET study, lower $^{11}$C-BU99008 binding correlated with worse global cognitive scores (MoCA assessments) in moderate/advanced Parkinson’s disease patients without distinguishing between demented and non-demented Parkinson’s disease patients.

In context with previous work, $^{11}$C-BU99008 PET data suggest that astrogliosis follows a non-linear trend in the course of Parkinson’s disease. By reviewing our data together with evidence from other reports in the field, we propose, that the extent of astrogliosis in non-demented patients might reach a relatively high level in early Parkinson’s disease. Nevertheless, in advanced Parkinson’s, with or without dementia, astrogliosis markers could measure within normal or mildly lower levels. This makes a point for a difference between ‘severe motor disease’ and ‘advanced Parkinson’s disease with dementia’.

A non-linear pattern of astrogliosis within PDD would likely be propagated by astrocytic α-synuclein accumulation. Indeed, previous cell culture studies in early Parkinson’s disease demonstrated that astrocytes can clear α-synuclein deposits from damaged neurons. However, pathology processes involve excessive astrocytic α-synuclein accumulation in the course of Parkinson’s disease. These processes suppress innate protective astrocytic responses and enable further neuronal damage. In a recent post-mortem study in advanced Parkinson’s disease, researchers found a negative correlation between levels of α-synuclein accumulation and markers of astrogliosis, including the GFAP. This point suggests that astrogliosis in regions of relevance for Parkinson’s disease, may steadily decline after a plateau of significant elevation. See evidence from markers of reactive astrocytosis in early Parkinson’s disease together with our PDD data.

Beyond Parkinson’s disease, a trend for steady decline of astrogliosis is supported by $^{11}$C-DED PET data (targeting the MAO-B) in carriers of autosomal dominant Alzheimer’s disease. Within a preserved region, it is possible, that astrocytes (in Parkinson’s disease as well as autosomal dominant Alzheimer’s disease), partly, retain the mechanism of beneficial α-synuclein clearance—reference to comparable $^{11}$C-BU99008 $V_T$ values in HC groups. However, in patients with marked regional degeneration (such as in advanced Parkinson’s disease), astrocytic clearance may be increasingly impaired due to severe reductions in neuronal cell count. Our PET and MRI data support this hypothesis and propose that a significant part of I$_2$BS measures in PDD is due to aging-related processes.

We are aware of potential methodological issues in the current work, including the size of our PDD group and the...
explorative nature of the study. At this point, we would like to make some disclosures to clarify our viewpoint and justify our approach. By reviewing the literature, we decided to exclude patients with previous lifetime exposure to MAO-Is. We understand this as a very important exclusion criterion for imaging the I2BS, especially with a relatively novel tracer. In the clinical environment, many patients with Parkinson’s disease are chronically prescribed irreversible MAO-Is, such as rasagiline. It would have been possible to recruit patients who routinely take these medicines and instruct them to temporarily withdraw for the purpose of this study. However, we deemed it important to have minimal risks from exogenous influences on our PET data and so excluded previous lifetime exposure.

We acknowledge that long scanning procedures are challenging for clinical research purposes. Recruiting Parkinson’s disease patients with confirmed dementia can be laborious, especially when the target is a group of patients who are able to provide informed consent, complete questionnaires, and execute high function tasks. More relevantly for the current work, eligible subjects were challenged to comply with the demands of long and invasive scanning procedures. For the present study, this refers to the difficulty to recruit patients with Parkinson’s disease with no previous exposure to MAO-Is, the difficulty to identify participants eligible for arterial cannulation (exclusion associated with commonly prescribed anticoagulants that form a contraindication for arterial cannulation), and capable of undergoing MR imaging. These points are made to explain the realistic approach for a small sample size for the disease under study.

We would like to state the lack of consensus on optimal PVC modelling and analysing 11C-BU99008 dynamic data. There may be a heterogeneity of 11C-BU99008 affinity for the I2BS in the general population. In a recent post-mortem

---

**Figure 3 Correlations.** Spearman’s correlations (two-tailed) between age and 11C-BU99008 VT values in subcortical regions, the cerebellum, and cortical regions in HCs (n = 18). Age and 11C-BU99008 VT values showed strong correlations for subcortical regions (r = +0.62, P = 0.004), the cerebellum (r = +0.54; P = 0.02), and cortical regions (r = +0.58, P = 0.009). * denotes significant at P < 0.05; ** denotes significant at P < 0.01; VT, volume of distribution.

---

**Table 3 Result of multiple linear regression analysis in healthy controls (n = 18) with interaction term**

| Variables       | Adj. R² | ΔR² | B    | SE  | β   | significance |
|-----------------|---------|-----|------|-----|-----|--------------|
| Age             | 0.908   | 0.917 | 0.33 | 0.32| 0.07| ns           |
| Age × Region    |         |      |      |     |     |              |
| Cortical        |         |      | 37.55| 5.20| 0.35| ***          |
| Subcortical     |         |      | 114.6| 5.20| 1.06| ***          |

* denotes significant at P < 0.05; *** denotes significant at P < 0.001.

Adj. R², adjusted R square; B, unstandardized coefficients; β, standardized coefficients beta; ΔR², R square change; ns, not statistically significant; Referent region for Region: cerebellum; SE, standard error.
In our study, all patients had Parkinson’s disease. Scholl M, Carter SF, Westman E, Qiu WW, Zheng RY. Neuroprotective effects of receptor imidazo

We acknowledge that some of our re

Scores are also influenced by educa

set is appropriate and a base for discussion and future

11C-BU99008 PET is a sensitive biomarker for the study of as

Conclusion

11C-BU99008 PET is a sensitive biomarker for the study of astrogliosis in vivo. Our results suggest that astrogliosis is commonplace and highly related to aging in a region-specific manner. The design of our study provides an important resource for future imaging studies on the role of reactive astrocytes in cognitive decline and related neurodegenerative diseases.

Acknowledgements

We would like to thank all participants, their families and carers. We are very grateful to all staff at the Hammersmith Hospital Campus for their work, technical and operational support. Z.Z. gratefully acknowledges the China Scholarship Council for supporting her stay as a visiting researcher at Imperial College London.

Funding

The study was funded by the National Institute for Health and care Research (NIHR) Imperial Biomedical Research Council (BRC), UK. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. Infrastructure for this research was provided by the NIHR Imperial Clinical Research Facility (CRF).

Competing interests

The authors report no competing interests.

Supplementary material

Supplementary material is available at Brain Communications online.

References

1. Liddelow SA, Barres BA. Reactive astrocytes: Production, function, and therapeutic potential. Immunity. 2017; 46(6):957–967.
2. Liddelow SA, Guttenplan KA, Clarke LE, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017; 541:481.
3. Zeng Z, Roussakis AA, Lao-Kaim NP, Piccini P. Astrocytes in Parkinson’s disease: From preclinical assays to in vivo imaging and therapeutic probes. Neurobiol Aging. 2020; 95:264–270.
4. Chun H, Lee CJ. Reactive astrocytes in Alzheimer’s disease: A double-edged sword. Neurosci Res. 2018; 126:44–52.
5. Carter SF, Herholz K, Rosa-Neto P, Pellerin L, Nordberg A, Zimmer ER. Astrocyte biomarkers in Alzheimer’s disease. Trends Mol Med. 2019; 25(2):77–95.
6. Scholl M, Carter SF, Westman E, et al. Early astrocytosis in autosomal dominant Alzheimer’s disease measured in vivo by multi-tracer positron emission tomography. Sci Rep. 2015; 5:16404.
7. Engler H, Lundberg PO, Ekbom K, et al. Multitracer study with positron emission tomography in creutzfeldt-jakob disease. Eur J Nucl Med Mol Imaging. 2003; 30(1):85–95.
8. Johansson A, Engler H, Blomquist G, et al. Evidence for astrocytosis in ALS demonstrated by [11C](l)-deprenyl-D2 PET. J Neurol Sci. 2007; 255(1):17–22.
9. Kumljen E, Nilsson A, Hagberg G, Längström B, Bergström M. PET With [11C]-deuterium-deprenyl and 18F-FDG in focal epilepsy. Acta Neurosci Scand. 2001; 103(6):360–366.
10. Qiu WW, Zheng RY. Neuroprotective effects of receptor imidazol

11. Roussakis AA, Piccini P. Molecular imaging of neuroinflammation in idiopathic Parkinson’s disease. *Int Rev Neurobiol.* 2018;141:347–363.

12. Tyacke RJ, Myers JFM, Venkataraman A, et al. Evaluation of (11)C-BU99008, a PET ligand for the imidazoline2 binding site in human brain. *J Nucl Med.* 2011;52(10):1597–1602.

13. Wilson H, Dervenoulas G, Pagano G, et al. Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson’s disease: An in vivo[11C-BU99008 PET study. *Brain.* 2019;142(10):3116–3128.

14. Calsolaro V, Matthews PM, Donat CK, et al. Astrocyte reactivity with late-onset cognitive impairment assessed in vivo using (11)C-BU99008 PET and its relationship with amyloid load. *Mol Psychiatry.* 2021;26(10):5848–5855.

15. Kumar A, Koistinen NA, Malarte ML, et al. Astroglial tracer BU99008 detects multiple binding sites in Alzheimer’s disease brain. *Mol Psychiatry* Oct 2021;26(10):5833–5847.

16. Hughes AJ, Daniel SE, Kiflord L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: A clinicopathological study of 100 cases. *J Neurol Neurosurg Psychiatry.* 1992;55(3):181–184.

17. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. *Mov Disord.* 2007;22(12):1689–1707; quiz 1837.

18. Goetz CG, Poewe W, Rascol O, et al. Movement disorder society task force report on the hoehn and yahr staging scale: Status and recommendations. *Mov Disord.* 2004;19(9):1020–1028.

19. Goetz CG, Tilley BC, Shaftman SR, et al. Movement disorder society-sponsored revision of the unified Parkinson’s disease rating scale (MDS-UPDRS): Scale presentation and clinimetric testing results. *Mov Disord.* 2008;23(15):2129–2170.

20. Folstein MF, Folstein SE, McHugh PR, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. *Mov Disord.* 2007;22(12):1689–1707; quiz 1837.

21. Goetz CG, Poewe W, Rascol O, et al. Movement disorder society task force report on the hoehn and yahr staging scale: Status and recommendations. *Mov Disord.* 2004;19(9):1020–1028.

22. Pagonabarraga J, Kulisevsky J, Llebaria G, Garcia-Sanchez C, Pascual-Sedano B, Girollon A. Parkinson’s disease-cognitive rating scale: A new cognitive scale specific for Parkinson’s disease. *Mov Disord.* 2008;23(7):998–1005.

23. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal cognitive assessment, MoCA: A brief screening tool for mild cognitive impairment. *J Am Geriatr Soc.* 2005;53(4):695–699.

24. Pagonabarraga J, Kulisevsky J, Llebaria G, Garcia-Sanchez C, Pascual-Sedano B, Girollon A. Parkinson’s disease-cognitive rating scale: A new cognitive scale specific for Parkinson’s disease. *Mov Disord.* 2008;23(7):998–1005.

25. Rosca EC, Simu M. Parkinson’s disease-cognitive rating scale for evaluating cognitive impairment in Parkinson’s Disease: A systematic review. *Brain Sci.* 2020;10(9):588.

26. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inventory: Comprehensive assessment of psychopathology in dementia. *Neurology.* 1994;44(12):2308–2314.

27. Wilson H, Niccolini F, Pellicano C, Politis M. Cortical thinning across Parkinson’s disease stages and clinical correlates. *J Neurol Sci.* 2019;398:31–38.

28. Gunn R, Coello C, Searle G. Molecular imaging and kinetic analysis toolbox (MIKAT) - A quantitative software package for the analysis of PET neuroimaging data. *J Nucl Med.* 2016;57(Suppl 2):1928.

29. Gonzalez-Escamilla G, Lange C, Teipel S, Buchert R, Grothe MJ. PETPVE12: An SPM toolbox for partial volume effects correction in brain PET - application to amyloid imaging with AV45-PET. *NeuroImage.* 2017;147:669–677.

30. Muller-Gartner HW, Links JM, Prince JL, et al. Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. *J Cereb Blood Flow Metab.* 1992;12(4):571–583.

31. Tong J, Meyer JH, Furukawa Y, et al. Distribution of monoamine oxidase proteins in human brain: Implications for brain imaging studies. *J Cereb Blood Flow Metab.* 2013;33(6):863–871.

32. Fowler JS, Volkow ND, Wang GJ, et al. Age-related increases in brain monoamine oxidase B in living healthy human subjects. *Neurobiol Aging.* 1997;18(4):431–435.

33. Rodriguez JJ, Yeh C-Y, Terziva S, Obalabria M, Kuljevicz-Nawrot M, Verkrhatsky A. Complex and region-specific changes in astroglial markers in the aging brain. *Neurobiol Aging.* 2014;35(1):15–23.

34. Nichols NR, Day JR, Lapin NJ, Johnson SA, Finch CE. GFAP mRNA increases with age in rat and human brain. *Neurobiol Aging.* 1993;14(5):421–429.

35. Clarke LE, Liddelow SA, Chakraborty C, Munch AE, Heiman M, Barres BA. Normal aging induces A1-like astrocyte reactivity. *Proc Natl Acad Sci.* 2018;115(8):E1896–E1905.

36. Garcia- Sebastian JA, Escriva PV, Guimon J. Imidazoline receptors and human brain disorders. *Ann N Y Acad Sci.* 1999;881:392–409.

37. Boronat MA, Olmos G, Garcia-Sebastian JA. Attenuation of tolerance to opioid-induced antinociception and protection against morphine-induced decrease of neurofilament proteins by idazoxan and other I2-imidazoline ligands. *Br J Pharmacol.* 1998;125(1):175–185.

38. Clarke LE, Liddelow SA, Chakraborty C, Munch AE, Heiman M, Barres BA. Normal aging induces A1-like astrocyte reactivity. *Proc Natl Acad Sci USA.* 2018;115(8):E1896–E1905.

39. Boisvert MM, Erikson GA, Skohre MN, Allen NJ. The aging astrocyte transcriptome from multiple regions of the mouse brain. *Cell Rep.* 2018;22(1):269–285.

40. Damir P, Hirsch EC, Zhang P, Agid Y, Javoy-Agid F. Glutathione peroxidase, glial cells and Parkinson’s disease. *Neuroscience.* 1993;51(1):1–6.

41. Knott C, Wilkin GP, Stern G. Astrocytes and microglia in the substantia nigra and caudate-putamen in Parkinson’s disease. *Parkinsonism Relat Disord.* 1999;5(3):115–122.

42. Song YJ, Halliday GM, Holton JL, et al. Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression. *J Neuropathol Exp Neurol.* 2009;68(10):1073–1083.

43. van den Berge SA, Kevenaar JT, Sluijs JA, Hol EM. Dementia in Parkinson’s disease correlates with alpha-synuclein pathology but not with cortical astrogliosis. *Parkinsons Dis.* 2012;2012:420957.

44. Matias I, Morgado J, Gomes FCA. Astrocyte heterogeneity: Impact to brain aging and disease. *Front Aging Neurosci.* 2019;11:59.

45. Tong J, Ang L-C, Williams B, et al. Low levels of astroglial markers in Parkinson’s disease: Relationship to a-synuclein accumulation. *Neurobiol Dis.* 2015;82:243–253.

46. Loria F, Vargas JY, Bousset L, et al. a-Synuclein transfer between neurons and astrocytes indicates that astrocytes play a role in degradation rather than in spreading. *Acta Neuropathol.* 2017;134(5):789–808.

47. Lee HJ, Suk JE, Patrick C, et al. Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleiopathies. *J Biol Chem.* 2010;285(12):9262–9272.

48. Rodriguez-Vitee E, Saint-Aubert L, Carter SF, et al. Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer’s disease. *Brain.* 2016;139( Pt 3):922–936.

49. Kumar A, Koistinen NA, Malarte ML, et al. Astroglial tracer BU99008 detects multiple binding sites in Alzheimer’s disease brain. *Mol Psychiatry.* 2021;26:5833–5847.